Rein Therapeutics Inc. (RNTX)
Rein Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Austin, TX, US. The stock last traded at $0.81, down 0.87% on the session, giving a market capitalisation of $22.6M. On trailing twelve-month figures it carries a trailing P/E of -0.43, a net margin of 0.0%. Its beta of 1.37 implies it has historically moved more than the broad market.
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Rein Therapeutics Inc. is most often compared with the following Healthcare names: